Liminal BioSciences Inc. (LMNL)
Stock Price:
$5.73 USD
0.02 (0.35%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
After-hours: $5.87 +0.14 (2.44%) Oct 26, 7:58 PM
Key Info
| Market Cap |
133.58M |
| Revenue (ttm) |
3.74M |
| Net Income (ttm) |
-207.80M |
| Shares Out |
23.31M |
| EPS (ttm) |
-9.78 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$5.73 |
| Previous Close |
$5.71 |
| Change ($) |
0.02 |
| Change (%) |
0.35% |
| Day's Open |
5.67 |
| Day's Range |
5.33 - 5.86 |
| Day's Volume |
582,567 |
| 52-Week Range |
5.33 - 31.45 |
More Stats
| Market Cap |
133.58M |
| Enterprise Value |
122.73M |
| Earnings Date (est) |
Nov 16, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
23.31M |
| Float |
6.79M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-9.78 |
| FCF / Share |
-4.94 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
15,016 |
| Short Ratio |
0.40 |
| Short % of Float |
0.22% |
| Beta |
2.02 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
35.68 |
| PB Ratio |
3.34 |
| Revenue |
3.74M |
| Operating Income |
-99.71M |
| Net Income |
-207.80M |
| Free Cash Flow |
-79.26M |
| Net Cash |
10.85M |
| Net Cash / Share |
0.47 |
| Gross Margin |
43.66% |
| Operating Margin |
-2,663.58% |
| Profit Margin |
-4,237.30% |
| FCF Margin |
-2,117.33% |
| ROA |
-42.40% |
| ROE |
-138.63% |
| ROIC |
-141.90% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
0 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Low
10.1
Current: $5.73
High
10.1
Target: 10.09
*Average 12-month USD price target from 1 stock analysts.
Financial Performance
Financial numbers in millions CAD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 4.90 | 24.63 | 22.31 |
| Revenue Growth | -80.09% | 10.4% | - |
| Gross Profit | 2.14 | -1.07 | 18.62 |
| Operating Income | -131 | -265 | -125 |
| Net Income | -208 | -280 | -130 |
| Shares Outstanding | 16.06 | 0.83 | 0.80 |
| Earnings Per Share | -12.81 | -235.95 | -137.85 |
| Operating Cash Flow | -99.39 | -82.45 | -123 |
| Capital Expenditures | -4.44 | -5.13 | -10.08 |
| Free Cash Flow | -104 | -87.58 | -133 |
| Cash & Equivalents | 61.29 | 7.39 | 38.87 |
| Total Debt | 47.07 | 128 | 49.12 |
| Net Cash / Debt | 14.21 | -120 | -10.25 |
| Assets | 165 | 103 | 265 |
| Liabilities | 70.16 | 166 | 106 |
| Book Value | 102 | -56.60 | 132 |
Numbers in millions CAD, except per-share numbers.
Company Details
| Full Name |
Liminal BioSciences Inc. |
| Country |
Canada |
| Employees |
300 |
| CEO |
Kenneth Harry Galbraith |
Stock Information
| Ticker Symbol |
LMNL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: LMNL |
Description
Liminal BioSciences, a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel treatments for patients suffering from diseases that have unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050) for the treatment of idiopathic pulmonary fibrosis, respiratory diseases, and Alström Syndrome. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The company operates in Canada, the United Kingdom, and the United States. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.